Background: Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
Patients with non-valvular atrial fibrillation treated with Xarelto (rivaroxaban) for stroke prevention were more likely to experience both intracranial haemorrhage...
Background: Adherence to oral anticoagulant (OAC) agents is important for patients with nonvalvular atrial fibrillation (NVAF) to prevent potentially severe adverse events.
The purpose of this trial is to demonstrate the efficacy and safety of dabigatran etexilate and different intensity warfarin for...
Background: The original non-vitamin K antagonist oral anticoagulant (NOAC) trials in nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies.
Objective: To evaluate the effectiveness of routine treatment (aneurysm coiling) vs 3 strategies for imaging surveillance compared with no preventive treatment or routine follow-up of tiny UIAs.
Results of a new interim analysis from a long-term study evaluating the safety and effectiveness of Pradaxa (dabigatran etexilate mesylate),...
The Bristol-Myers Squibb-Pfizer Alliance presented new real-world evidence (RWE) from a sub-analysis of the ARISTOPHANES study comparing the safety and...
Bristol-Myers Squibb/Pfizer announced findings from NAXOS, the largest real-world data analysis on oral anticoagulant (OAC) effectiveness and safety in Europe...
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.